We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Oruba Showcases Innovative Self-Operating Uroflowmeter

By LabMedica International staff writers
Posted on 12 Nov 2024

Oruba Technology & Innovation (Langenfeld, Germany) is showcasing its innovative self-operating uroflowmeter, Oruflow, including both the urinal and toilet versions, at MEDICA 2024. More...

Oruflow is the world’s first self-operating uroflowmeter. As a point-of-care (POC) diagnostic device, it eases and accelerates the uroflowmetry process in a hygienic and comfortable atmosphere, making it a crucial part of every hospital and urology clinic. Oruba Oruflow is available in two versions for urology clinics – the Oruflow i POC diagnostic urinal and the Oruflow h POC diagnostic toilet. Both the devices feature an on-board screen to assist patients before and after examinations. The patient can receive the results of the examination in seconds without any operator guidance. The patient uses the hospital barcode to let Oruba Oruflow save the examination report into the hospital information system automatically.

The Oruflow h features a specially designed adapter enabling accurate and comfortable uroflowmetry testing for individuals of all gender types and ages. This ergonomic adapter is designed to accommodate anatomical differences such as the urination posture of women, ensuring a seamless and user-friendly experience. This adaptor is also suitable for children, providing the same level of comfort and accuracy. Oruflow h introduces a groundbreaking feature: The anatomical design of the toilet which separates stool and urine. With this feature, Oruflow h continues working even after accidental defecation, ensuring reliable performance in all conditions.

Both the Oruflow models have an EMG (electromyography) option, which provides synchronized uroflowmetry and EMG measurements. While the Oruflow measures the urine flow rate, the EMG module measures the electrical activity of the muscles before, during, and after urination to evaluate urinary problems. In biofeedback, EMG results are displayed using a bird game interface which is also virtual reality-compatible. When the patient contracts their muscles, the bird flaps. The doctor can change the scale and see the results synchronously.

Related Links:
Oruba Technology & Innovation


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HPV Test
Allplex HPV28 Detection
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.